CaginiCDi PasqualeGLupidiMTimolol 0.1% gel versus timolol 0.5% eyedrops in the prophylaxis of ocular hypertension after phacoemulsification surgery. Eur J Ophthalmol. 2014;24:857–61.
2.
MillsKBBlind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the reatment of simple chronic glaucoma. Br J Ophthalmol. 1983;67:216–9.
3.
SchenkerHISilverLHLong-term intraocular pressure-lowering efficacy and safety of timolol maleate gel-forming solution 0.5% compared with Timoptic XE 0.5% in a 12-month study. Am J Ophthalmol. 2000;130:145–50.
4.
ZimmermanTJKaufmanHETimolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601–4.
5.
CampbellSHHickey-DwyerMHardingSPDouble-masked three-period crossover investigation of timolol in control of raised intraocular pressure. Eye. 1993;7:105–8.
6.
DicksteinKAarslandTComparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol. 1996;121:367–71.
7.
StenhagenMNordellEElmståhlSFalls in elderly people: a multifactorial analysis of risk markers using data from the Swedish general population study ‘Good ageing in Skåne.’Aging Clin Exp Res. 201325:59–67.
